Articles from AMRA Medical

AMRA Medical is proud to share its inclusion in the World’s Top HealthTech Companies list, published today by TIME in collaboration with Statista. This recognition positions AMRA among an elite group of global innovators that are leading healthcare transformation.

Researchers from AMRA Medical, in collaboration with Pfizer, Inc., have recently published a study demonstrating the utility of AMRA’s muscle biomarkers as surrogate endpoints to describe functional changes in participants with Duchenne Muscular Dystrophy (DMD). The study explored changes in lean muscle volume (LMV), muscle fat fraction (MFF), and muscle fat infiltration (MFI) – as well as their relationship to changes in physical performance as described by the North Star Ambulatory Assessment (NSAA) – in order to determine whether MRI-based muscle biomarkers have the potential to detect and quantify clinically meaningful changes in DMD.

AMRA Medical, as part of a collaborative effort composed of researchers from the University of Glasgow, University Hospitals Cleveland, and Eli Lilly and Company, recently conducted a detailed post-hoc analysis of Lilly’s SURPASS-3 trial. The analysis explored data from the trial to determine the association of tirzepatide treatment with changes in thigh muscle volume, muscle volume z-score and muscle fat infiltration in people with type 2 diabetes (T2D)

AMRA Medical, in collaboration with researchers from National Center of Neurology and Psychiatry in Tokyo as well as Japanese pharmaceutical company Daiichi-Sankyo, are excited to announce the publication of a recent study investigating the utility of AMRA’s fat-referenced MRI measurements in inflammatory myopathies - specifically, sporadic inclusion body myositis (sIBM).

A recent publication in the Annals of Hepatology utilizing the AMRA® MAsS Scan, a body-composition analysis service powered by the FDA 510(k) cleared AMRA® Profiler 4 device, explored the feasibility of using AMRA’s specialized MRI-based analysis for generating muscle composition assessments in patients with end-stage liver disease (ESLD). These findings come during a critical period in liver disease research, as methods to combat challenges associated with identifying and treating sarcopenia and frailty in ESLD have become front-of-mind for researchers and clinicians, in an effort to address unmet needs in the highly-burdened liver disease population.

AMRA Medical, in conjunction with collaborators at the University of Oslo, have recently published the results of a study that examines the relationship that antidepressants (ADs), particularly serotonin-selective reuptake inhibitors (SSRIs) and tricyclic antidepressants (TCAs), have with muscle health and cardiometabolic risk profiles. As part of the CoMorMent project, a Horizon 2020-funded research initiative that aims to explore how and why mental health interacts with cardiovascular disease, the study comes at a crucial time as antidepressant usage globally continues to increase. As a result, new methods of determining the extent to which antidepressants affect general well-being become front-of-mind for drug developers and clinicians, given the increased predisposition to cardiovascular disease (CVD) and poor impact on metabolic health that AD users often experience.

A focused review titled “Muscle Mass and Glucagon-like Peptide-1 Receptor Agonists: Adaptive or Maladaptive Response to Weight Loss?” was recently published in the renowned cardiovascular scientific journal, Circulation. Authored by AMRA Medical’s Dr. Jennifer Linge, professor Andreas Birkenfeld of University Hospital Tübingen, and associate professor Ian Neeland of University Hospitals Cleveland, the article discusses several aspects of the response associated with weight loss with respect to muscle health.

AMRA Medical, a leading force in the development of MRI-based body composition analyses and biomarkers, is pleased to announce their EU Medical Device Regulation (MDR) certificate for the cutting-edge AMRA® Profiler 4 body composition analysis device.

AMRA Medical - a health informatics and precision medicine company that is pioneering body composition research through gold-standard MRI-based analysis platforms - collaborated on a study driven by University of Texas Southwestern and University Hospital Cleveland to publish new data revealing the effect of liraglutide treatment on muscle composition in adults with obesity.

AMRA Medical, a health informatics and precision medicine company that is pioneering body composition research through gold-standard MRI-based analysis platforms, in collaboration with Linköping University, is pleased to announce the completion of baseline enrollment for the innovative ACCESS-ESLD (A Rapid, Non-invasive, Clinical Surveillance for CachExia, Sarcopenia, Portal HypertenSion, and Hepatocellular Carcinoma in End-Stage Liver Disease) study. The nationally-comprised study population includes 150 liver cirrhosis patients aged 18 and up, with no liver transplant history or contraindications to performing an MRI examination, enrolled from one of three Swedish liver care clinics located in Linköping, Eksjö, or Jönköping. Over a duration of 2 years, patients will be assessed every 6 months with a comprehensive clinical examination and a whole-body MRI examination.

Researchers from AMRA Medical, a leading health informatics company providing body composition analysis through magnetic resonance imaging (MRI), together with Eli Lilly, and researchers from Nantes Université, University Hospitals Cleveland, and Linköping University used visceral-, subcutaneous-, and liver fat z-scores derived from MRI to investigate changes in fat distribution patterns in patients with type 2 diabetes (T2D) participating in SURPASS-3 MRI.

AMRA Medical has a large presence at this year’s The Liver Meeting®. A total of nine abstracts will be presented, focusing on how AMRA’s MRI-based muscle assessment score (MAsS) biomarkers are linked to liver disease severity and progression.

Visceral fat, also known as Visceral Adipose Tissue (VAT), is the adipose tissue inside the abdominal cavity. VAT is a central risk factor for Non-Alcoholic Fatty Liver Disease (NAFLD), liver cirrhosis, cardiovascular disease (CVD), and type-2 diabetes (T2D). This study validates, prospectively, the precision and repeatability of AMRA Medical’s VAT biomarker for use in clinical trials.

Two analyses have shed light on an important factor when evaluating treatments that significantly reduce bodyweight: their effect on muscle composition. For their multicenter SURPASS-3 MRI study, Eli Lilly and Company selected AMRA® Researcher to measure muscle volume and muscle fat infiltration.

AMRA Medical, the global leader in body composition analysis, is pleased to announce a set of significant strategic changes aimed at accelerating growth in critical areas while solidifying our position as the gold standard for body composition analysis in clinical areas of research.

AMRA Medical, and their collaborators, will present seven abstracts along the whole disease progression line of chronic liver disease, with studies involving individuals with early liver disease (non-alcoholic fatty liver disease; NAFLD) to cirrhosis to liver transplant. The data presented suggest that it may be possible to use the same objective, accurate, and precise magnetic resonance (MR)-based technology and informatics-based image analysis, to assess both physical frailty and sarcopenia throughout the course of disease. Those attending AASLD The Liver Meeting in November can learn more about how AMRA’s technology and informatics were used in these studies and how it all underpins our clinical applications, AMRA® MAsS scan and AMRA® BCP scan, by attending the abstract presentations or visiting AMRA’s exhibition booth #731.

AMRA Medical today announced they have signed a definitive agreement with Human Longevity Inc. (HLI) to offer AMRA® BCP Scan Report to its members as part of their 100+ Precision Longevity Care membership program.